Thus, BCR-ABL1 suffices to shut down canonical TGF-β signaling in CML even in the absence of Smad4 deletions or inactivating mutations. The gene discussed is TGFB1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.